Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity

Journal of Internal Medicine

Volumn 270, Issue 1, 2011, Pages 76-84

  Reuter, S E ^a,b   Evans, A M ^a,b  

^a University of South Australia City East Campus   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Acylcarnitine; Carnitine; Carnitine palmitoyltransferase; Chronic fatigue syndrome; Fatty acid

Indexed keywords

ADIPYL LEVO CARNITINE; BUTYRYL LEVO CARNITINE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; DECADIENOYL LEVO CARNITINE; DECANOYL LEVO CARNITINE; DECENOYL LEVO CARNITINE; DODECENOYL LEVO CARNITINE; GLUTARYL LEVO CARNITINE; HEXANOYL LEVO CARNITINE; HEXENOYL LEVO CARNITINE; HYDROXY BUTYRYL LEVO CARNITINE; HYDROXY ISOVALERYL LEVO CARNITINE; LAUROYL EVO CARNITINE; LEVACECARNINE; LINOLEYL LEVO CARNITINE; MALONYL LEVO CARNITINE; OCTANOYL LEVO CARNITINE; OCTENOYL LEVO CARNITINE; OLEYL LEVO CARNITINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROPIONYLCARNITINE; SEBACYL LEVO CARNITINE; SOVALERYL LEVO CARNITINE; SUBERYL LEVO CARNITINE; SUCCINYL LEVO CARNITINE; TIGLYL LEVO CARNITINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HOMEOSTASIS; HUMAN; MALE; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUESTIONNAIRE;

ADULT; AGED; CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; EPIDEMIOLOGIC METHODS; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 79959369342     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02341.x     Document Type: Article

References (48)

1. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 221-36.
2. Plioplys S, Plioplys AV. Chronic fatigue syndrome (myalgic encephalopathy). South Med J 1995; 88: 993-1000.
3. Plioplys S, Plioplys AV. Chronic fatigue syndrome (myalgic encephalopathy): a review. Chic Med 1995; 98: 11-5.
4. Royal Australasian College of Physicians Working Group. Chronic fatigue syndrome clinical practice guidelines - 2002. Med J Aust 2002; 176: S17-56.
5. Reynolds KJ, Vernon SD, Bouchery E, Reeves WC. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2004; 2: 4.
6. Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: individual and societal costs. Dyn Med 2008; 7: 6.
7. Lloyd AR, Pender H. The economic impact of chronic fatigue syndrome. Med J Aust 1992; 157: 599-601.
8. Anderson JS, Ferrans CE. The quality of life of persons with chronic fatigue syndrome. J Nerv Ment Dis 1997; 185: 359-67.
9. Lombardi VC, Ruscetti FW, Das Gupta J et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326: 585-9.
10. Erlwein O, Kaye S, McClure MO et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE 2010; 5: e8519.
11. Groom HC, Boucherit VC, Makinson K et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010; 7: 10.
12. Lo SC, Pripuzova N, Li B et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci USA 2010; 107: 15874-9.
13. Switzer WM, Jia H, Hohn O et al. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010; 7: 57.
14. van Kuppeveld FJ, de Jong AS, Lanke KH et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 2010; 340: c1018.
15. Bremer J. Carnitine - Metabolism and functions. Physiol Rev 1983; 63: 1420-80.
16. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179: 899-902.
17. Bieber LL. Carnitine. Annu Rev Biochem 1988; 57: 261-83.
18. Famularo G, Matricardi F, Nucera E, Santini G, De Simone C. Carnitine deficiency: Primary and secondary syndromes. In: De Simone C, Famularo G, eds Carnitine Today. Austin, USA: RG Landes Company, 1997; 119-61.
19. Pons R, De Vivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995; 10(Suppl 2): S8-24.
20. Scholte HR, Rodrigues Pereira R, de Jonge PC, Luyt-Houwen IEM, Verduin MHM, Ross JD. Primary carnitine deficiency. J Clin Chem Clin Biochem 1990; 28: 351-7.
21. Kuratsune H, Yamaguti K, Watanabe Y et al. Acylcarnitine and chronic fatigue syndrome. In: De Simone C, Famularo G, eds Carnitine Today. Austin, USA: RG Landes Company, 1997; 195-213.
22. Kuratsune H, Yamaguti K, Lindh G et al. Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med 1998; 2: 51-6.
23. Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18(Suppl 1): S62-7.
24. Kuratsune H, Yamaguti K, Takahashi M, Tagawa S, Machii T, Kitani T. Abnormal cellular carnitine metabolism in chronic fatigue syndrome. EOS J Immunol Immunopharmacol 1995; 15: 40-4.
25. Li YJ, Wang DX, Bai XL et al. [Clinical characteristics of patients with chronic fatigue syndrome: analysis of 82 cases]. Zhonghua Yi Xue Za Zhi 2005; 85: 701-4. (Abstract).
26. Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995; 32: 132-8.
27. Jones MG, Goodwin CS, Amjad S, Chalmers RA. Plasma and urinary carnitine and acylcarnitines in chronic fatigue syndrome. Clin Chim Acta 2005; 360: 173-7.
28. Majeed T, De Simone C, Famularo G, Marcellini S, Behan PO. Abnormalities of carnitine metabolism in chronic fatigue syndrome. Eur J Neurol 1995; 2: 425-8.
29. Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997; 43: 2106-13.
30. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49: 1797-817.
31. Soetekouw PM, Wevers RA, Vreken P et al. Normal carnitine levels in patients with chronic fatigue syndrome. Neth J Med 2000; 57: 20-4.
32. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
33. Taylor RR, Jason LA, Torres A. Fatigue rating scales: an empirical comparison. Psychol Med 2000; 30: 849-56.
34. Edwards RH, Newham DJ, Peters TJ. Muscle biochemistry and pathophysiology in postviral fatigue syndrome. Br Med Bull 1991; 47: 826-37.
35. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009; 2: 1-16.
36. Maes M, Mihaylova I, Leunis JC. In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett 2005; 26: 745-51.
37. Leonhardt M, Langhans W. Fatty acid oxidation and control of food intake. Physiol Behav 2004; 83: 645-51.
38. Niot I, Gresti J, Boichot J et al. Effect of dietary n-3 and n-6 polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver. Lipids 1994; 29: 481-9.
39. Vamecq J, Vallee L, de la Porte PL et al. Effect of various n-3/n-6 fatty acid ratio contents of high fat diets on rat liver and heart peroxisomal and mitochondrial beta-oxidation. Biochim Biophys Acta 1993; 1170: 151-6.
40. Beermann C, Jelinek J, Reinecker T, Hauenschild A, Boehm G, Klor HU. Short term effects of dietary medium-chain fatty acids and n-3 long-chain polyunsaturated fatty acids on the fat metabolism of healthy volunteers. Lipids Health Dis 2003; 2(Art 1): 1-10.
41. Guebre-Egziabher F, Rabasa-Lhoret R, Bonnet F et al. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects. Eur J Clin Nutr 2008; 62: 1287-93.
42. Yoon HR, Hong YM, Boriack RL, Bennett MJ. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res 2003; 53: 788-92.
43. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997; 35: 16-23.
44. Vermeulen RCW, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004; 66: 276-82.
45. Puri BK. The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 399-401.
46. Puri BK. Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J Clin Pathol 2007; 60: 122-4.
47. Tamizi farB, Tamizi B. Treatment of chronic fatigue syndrome by dietary supplementation with omega-3 fatty acids - A good idea? Med Hypotheses 2002; 58: 249-50.
48. Piccoli C, Quarato G, Ripoli M et al. HCV infection induces mitochondrial bioenergetic unbalance: causes and effects. Biochim Biophys Acta 2009; 1787: 539-46.